Trilaciclib Dihydrochloride

曲拉西利二盐酸盐

Report date: 2026/03/31 20:00:21
NME

Base Information

Drug NameTrilaciclib Dihydrochloride
Drug Alias Name曲拉西利盐酸曲拉西利COSELA科赛拉G1T28 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 6 inhibitorsCyclin-dependent kinase 4 inhibitors
TargetsCyclin-dependent kinase 6Cyclin-dependent kinase 4
Therapy Area/IndicationsChemotherapy induced poisoningMetastatic breast cancerSolid tumours +[9] 
Global Approved IndicationsChemotherapy-induced myelosuppression
Approved Indications in ChinaChemotherapy-induced myelosuppression
Original Approved Country/TerritoryUnited States
Original Approved Date2021/02/12
Country/TerritoryBelgiumBosnia and HerzegovinaBulgaria +[22] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesG1 Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesC.H. Boehringer Sohn Ag & Co. KgPharmacosmos Therapeutics IncG1 Therapeutics Inc +[6] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursChemotherapy-induced myelosuppressionSmall Cell Lung Carcinoma +[5] 
Inactive IndicationsChemotherapy induced poisoningMetastatic breast cancerColorectal Neoplasms +[4] 

Other Information

ATC CodeL01XE
Related LinksWikipediaDrugBankKEGG